Camelid TB Serology Quarterly Report: 1st October to 31st December 2015
Source: environment.data.gov.uk (2024-10-03)

Camelid TB Serology Quarterly Report. Camelid TB Serology Quarterly Report.

Camelid TB Serology
Quarterly Report
Number: 3
Report Period 1st October to 31st December 2015
Issued 05 January 2016

Submission Reason
Explanation
APHA /DEFRA
At Government expense
Parallel Test:
PAR-TB
TB breakdown herd with confirmed M. bovis infection (including Wales where Officially
TB Free Withdrawn [OTFW] status is determined on epidemiological grounds)
PAR-SUS
TB strongly suspected but not currently confirmed by laboratory culture – herd under
restrictions
PAR-TRC
Forward  tracing(s) from an M. bovis-infected camelid herd (includes camelid herds in
Wales only co-located on the same premises with infected cattle, sheep, deer, goats
& pigs)
Serial Test:
SER-CONT
Herd not under restriction but contiguous to a TB-infected herd
SER-COL
Herd not under restriction but co-located with an infected herd of cattle, deer, goats
etc. (Eng & Scot only)
SER-EPI
Herd not under restriction but TB tested due to an epidemiological link with a known
infected herd (e.g. back-tracing)
Commercial/Private
At Owner expense
SER-MVT
Pre- or post-movement test
SER-EXP 
Pre-export test
SER-DIAG
Diagnostic to exclude TB from a differential diagnoses in a herd not restricted (TB
strongly suspected)
SER-RHT
Monitoring - voluntary routine testing (herd nor restricted)
Quarterly Camelid Serology Report
Test Criteria
The camelid TB serology (antibody) test comprises two separate antibody tests in a test package that can be applied
flexibly to increase the sensitivity or specificity of the test as required, by using a parallel or serial test interpretation
respectively. The sensitivity and specificity values of combined antibody testing for camelids were described under AHVLA
Project FT1477 as follows (see also Rhodes et al., 2012);
Sensitivity = 81.3% [71.9-91.6]    [95% confidence intervals]
Specificity = 95.8% [93.3-98.2]
Parallel Test (e.g. confirmed breakdown herd test – for increased sensitivity):
Serial Test (e.g. movement test – for increased specificity):
Sensitivity = 55.8% [42.3-69.3]
Specificity = 99.7% 99.1-100]
N.B. The above combined test used by APHA from 1st October 2014 comprised the IDEXX ELISA and the Chembio
STAT-PAK lateral flow tests. Replacement of the STAT-PAK with the DPP VetTB lateral flow test by Chembio led to the
exchange of the STAT-PAK in the APHA camelid combined test with the new DPP VetTB test. APHA validation data
showed the DPP VetTB to have similar test specificities when used in the above combined test with the IDEXX ELISA
(Parallel 92.9% [89.6-96.2]; Serial 99.6% [98.7-100]). Preliminary data also suggested that the sensitivity of the DPP
VetTB is equivalent to that of the STAT-PAK.
Rhodes, S., Holder, T., Clifford, D., Dexter, I., Brewer, J., Smith, N., Waring, L., Crawshaw, T., Gillgan, S., Lyashchenko,
K., Lawrence, J., Clarke, J., de la Rua-Domenech, R., Vordermeier, M., 2012. Evaluation of gamma interferon and
antibody tuberculosis tests in alpacas. Clin Vaccine Immunol 19, 1677-1683.

Quarterly Camelid Serology Report
05 Jan 2016
Table 1a
Country
No.
Samples
Tested
England
441
Wales
124
Non GB
33
Total for Q4
598
Number of Samples tested and Submission Reason  2015 Q4 (October - December)
Table 1b
Submission
Reason
No.
Samples
Tested
Parallel
PAR-SUS
2
PAR-TB
123
PAR-TRC
10
Parallel
Sum:
135
Serial
SER-CONT
427
Serial
Sum:
427
Commercial/Private Testing SER-EXP
1
SER-MVT
35
Commercial/Private Testing
Sum:
36
Total for Q4
Sum:
598

Quarterly Camelid Serology Report
05 Jan 2016
Table 2a
Country
No.
Samples
Tested
England
1427
Wales
409
Non GB
111
Total for Q4
1947
Number of Samples tested and Submission Reason 2015 up to end of Q4 (January - December)
Table 2b
APHA/DEFRA
Submission
Reason
No.
Samples
Tested
Parallel
PAR-SUS
41
PAR-TB
349
PAR-TRC
54
Parallel
Sum:
444
Serial
SER-COL
69
SER-CONT
865
SER-EPI
411
Serial
Sum:
1345
Commercial/Private Testing
SER-DIAG
35
SER-EXP
1
SER-MVT
118
SER-RHT
4
Commercial/Private Testing
Sum:
158
Total for 2015 up to end
of Q4
1947

Quarterly Camelid Serology Report
05 Jan 2016
Table 3a
Submissions Received and Test Positivity in 2015 Q4
Country
Submission
Reason
No.
Submissions
No. Samples
Tested
No.
Positive
Samples
% Positive
Samples
England
Parallel
PAR-SUS
1
2
1
50.0%
PAR-TB
3
123
21
17.1%
PAR-TRC
1
7
2
28.6%
Parallel
5
132
24
18.2%
Serial
SER-CONT
16
306
4
1.3%
Serial
16
306
4
1.3%
Commercial/Private Testing
SER-EXP
1
1
0
0
SER-MVT
1
2
0
0
Commercial/Private Testing
2
3
0
0
England Total
23
441
28
6.3%
Wales
Parallel
PAR-TRC
1
3
2
66.7%
Parallel
1
3
2
66.7%
Serial
SER-CONT
4
121
8
6.6%
Serial
4
121
8
6.6%
Wales Total
5
124
10
8.1%
Non GB
Commercial/Private Testing
SER-MVT
3
33
0
0
Commercial/Private Testing
3
33
0
0
Non GB Total
3
33
0
0
Totals for Q4
31
598
38
6.4 %
Test Positivity in 2015 Q4 (October - December)

Quarterly Camelid Serology Report
05 Jan 2016
Table 3b
Submissions Received and Test Positivity in 2015 up to the end of Q4
Country
Submission
Reason
No.
Submissions
No. Samples
Tested
No.
Positive
Samples
% Positive
Samples
England
Parallel
PAR-SUS
4
39
7
17.9%
PAR-TB
12
344
88
25.6%
PAR-TRC
6
42
13
31.0%
Parallel
22
425
108
25.4%
Serial
SER-COL
12
69
1
1.4%
SER-CONT
47
484
11
2.3%
SER-EPI
10
405
39
9.6%
Serial
69
958
51
5.3%
Commercial/Private Testing
SER-DIAG
7
35
2
5.7%
SER-EXP
1
1
0
0
SER-MVT
3
4
1
25.0%
SER-RHT
2
4
0
0
Commercial/Private Testing
13
44
3
6.8%
England Total
104
1,427
162
11.4%
Wales
Parallel
PAR-SUS
1
2
2
100.0%
PAR-TB
1
5
3
60.0%
PAR-TRC
4
12
3
25.0%
Parallel
6
19
8
42.1%
Serial
SER-CONT
21
381
28
7.3%
SER-EPI
1
6
0
0
Serial
22
387
28
7.2%
Commercial/Private Testing
SER-MVT
1
3
0
0
Commercial/Private Testing
1
3
0
0
Wales Total
29
409
36
8.8%
Non GB
Commercial/Private Testing
SER-MVT
12
111
9
8.1%
Commercial/Private Testing
12
111
9
8.1%
Non GB Total
12
111
9
8.1%
Totals up to
end Q4
145
1,947
207
10.6 %
Test Positivity in 2015 up to end of Q4 (January - December)

Quarterly Camelid Serology Report
05 Jan 2016
Submissions Received in 2015 up to end of Q4
Analysis
Analysis Description
Q1
No.
samples
tested
Q2
No.
samples
tested
Q3
No.
samples
tested
Q4
No.
samples
tested
Totals up to end Q4
TC0503
Camelid TB Enferplex - 2
Spot
101
101
TC0603
Camelid TB Enferplex - 4
Spot
55
55
TC0615
Camelid TB DPP VetTB
antibody test
496
442
938
TC0677
Lateral flow for
Mycobacterium bovis
306
346
201
853
TC0867
Camelid TB Antibody
ELISA
306
346
697
543
1,892
Table 4: Number of samples Tested by Test Code